PropertyValue
?:abstract
  • In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.
?:creator
?:doi
  • 10.1038/s41392-021-00481-y
?:doi
?:journal
  • Signal_Transduct_Target_Ther
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/0bf192c722ca70f99237549a0a221988c037a01a.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7851657.xml.json
?:pmcid
?:pmid
?:pmid
  • 33531462.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
?:type
?:year
  • 2021-02-02

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/4rn5eugg>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/4rn5eugg>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all